Abbott Laboratories (NYSE:ABT) was the target of unusually large options trading on Tuesday. Traders purchased 10,515 call options on the company. This represents an increase of approximately 419% compared to the average daily volume of 2,026 call options.
Several equities research analysts recently commented on ABT shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a research report on Thursday, August 3rd. Cowen and Company reissued an “outperform” rating and issued a $48.00 target price on shares of Abbott Laboratories in a research report on Saturday, April 22nd. TheStreet raised Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, May 31st. Finally, Stifel Nicolaus raised their target price on Abbott Laboratories from $49.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, May 31st. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $51.93.
In other news, insider Jared Watkin sold 552 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $47.97, for a total transaction of $26,479.44. Following the completion of the transaction, the insider now directly owns 47,090 shares in the company, valued at $2,258,907.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sharon J. Bracken sold 2,000 shares of the stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total value of $98,320.00. Following the sale, the insider now directly owns 28,806 shares in the company, valued at $1,416,102.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 218,702 shares of company stock valued at $10,149,733. 0.76% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in ABT. Sullivan Bruyette Speros & Blaney LLC increased its stake in Abbott Laboratories by 1.6% in the second quarter. Sullivan Bruyette Speros & Blaney LLC now owns 18,052 shares of the healthcare product maker’s stock worth $878,000 after buying an additional 278 shares during the last quarter. Motco increased its stake in Abbott Laboratories by 213.7% in the second quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock worth $140,000 after buying an additional 1,962 shares during the last quarter. Homrich & Berg increased its stake in Abbott Laboratories by 31.7% in the second quarter. Homrich & Berg now owns 8,480 shares of the healthcare product maker’s stock worth $412,000 after buying an additional 2,039 shares during the last quarter. Allen Investment Management LLC increased its stake in Abbott Laboratories by 45.3% in the second quarter. Allen Investment Management LLC now owns 11,627 shares of the healthcare product maker’s stock worth $565,000 after buying an additional 3,627 shares during the last quarter. Finally, QCI Asset Management Inc. NY increased its stake in shares of Abbott Laboratories by 4.2% in the second quarter. QCI Asset Management Inc. NY now owns 248,296 shares of the healthcare product maker’s stock valued at $12,070,000 after buying an additional 10,099 shares in the last quarter. Institutional investors and hedge funds own 70.98% of the company’s stock.
Shares of Abbott Laboratories (ABT) traded down 0.85% during mid-day trading on Tuesday, reaching $48.88. The company had a trading volume of 3,389,663 shares. Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $51.13. The company has a market capitalization of $84.82 billion, a price-to-earnings ratio of 68.46 and a beta of 1.07. The stock has a 50 day moving average of $49.10 and a 200-day moving average of $45.36.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion during the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 3.44% and a net margin of 4.07%. Abbott Laboratories’s revenue was up 24.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 EPS. On average, analysts expect that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be issued a dividend of $0.265 per share. The ex-dividend date of this dividend is Wednesday, July 12th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.17%. Abbott Laboratories’s payout ratio is 149.30%.
ILLEGAL ACTIVITY WARNING: “Investors Buy High Volume of Abbott Laboratories Call Options (NYSE:ABT)” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/08/08/investors-buy-high-volume-of-call-options-on-abbott-laboratories-nyseabt-updated-updated-updated.html.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.